COMMUNIQUÉS West-GlobeNewswire

Lifeward Reports First Quarter 2026 Financial Results
15/05/2026
Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6. 5 million in cash and promising Protein Oral Delivery ™ biomed technology , with lead asset ORMD-0801 [...]
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
15/05/2026
PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced UGN-103 achieved a [...]
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
15/05/2026
Federal Officials, Researchers, Clinicians and Biopharma Leadership Convene d by Psychedelic Medicine Coalition at the National Press Club Vancouver, Canada, May 15, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( [...]
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
15/05/2026
Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic Diseases MELBOURNE, Australia, May 15, 2026 (GLOBE NEWSWIRE [...]
LifeMD to Participate in Upcoming Investor Conferences
15/05/2026
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading platform for virtual primary care services, today announced that management will be participating in two upcoming investor conferences. [...]
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
15/05/2026
SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
15/05/2026
Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026 following 45 subject enrollment milestone [...]
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
15/05/2026
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds [...]
Vaso Corporation Announces Financial Results for First Quarter of 2026
15/05/2026
PLAINVIEW, N.Y., May 15, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional sales services, and [...]
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
15/05/2026
SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an aggregate of 21, [...]
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
15/05/2026
New Taipei City, Taiwan, May 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization [...]
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
15/05/2026
Completed enrollment in first cohort of Phase 1b challenge study evaluating CDI-988 as a preventive and as a treatment for norovirus infection, began enrollment in prevention and treatment cohorts Highlighted CDI-988’s [...]
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
15/05/2026
Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing therapies that target innate immune dysfunction, today announced that results from its [...]
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
15/05/2026
100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale (cVM-IGA Bleeding) at Week 12 (+2.5 [...]
Profusa Announces Listing Transfer to The Nasdaq Capital Market
15/05/2026
BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring [...]
Kanghong Pharmaceutical and Vanotech Announce Positive Phase 2b Results for KH607 in Major Depressive Disorder
15/05/2026
Phase 2b Trial Met Primary Endpoint, Demonstrating Strong Efficacy and Favorable Safety Profile; Phase 3 Planned CHENGDU, China and ROCKAWAY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Kanghong Pharmaceutical and Vanotech [...]
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
15/05/2026
Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026 PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026 New Drug Application ( [...]
Davos Alzheimer’s Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer’s Policy, Research and Care
15/05/2026
Davos Alzheimer’s Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer’s Policy, Research and Care Geneva, Switzerland, May 15, 2026 - The Davos Alzheimer’s [...]
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
15/05/2026
Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026 AACR and ASGCT presentations showcase durable survival and [...]

Pages